Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

NCT03599362 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped PI departure from institution

Conditions

Pancreatic Cancer

Interventions

DRUG: Nivolumab + Cabiralizumab
RADIATION: Stereotactic Body Radiotherapy (SBRT)

Sponsor

NYU Langone Health